- 1 Predicting the risks for stroke, cardiovascular disease, and
- 2 peripheral vascular disease among people with type 2 diabetes

3 with artificial intelligence models: a systematic review and meta-

- 4 analysis
- 5 Aqsha Nur,¹ Sydney Tjandra,² Defin Yumnanisha,² Arnold Keane,² Adang Bachtiar¹
- 6 ¹ Faculty of Public Health, University of Indonesia.
- ⁷ ² Faculty of Medicine, University of Indonesia.
- 8 Correspondence should be addressed to Sydney Tjandra: sydney.tjandra@ui.ac.id

9 Abstract

10 **Objectives:** This systematic review and meta-analysis aim to explore the performance of

11 machine learning algorithms in predicting the risk of macrovascular complications among

12 individuals with T2DM, specifically, the predictive capabilities of AI models in forecasting

- 13 stroke, CVD, and PVD in LMICs.
- Design: Systematic review and meta-analysis of studies reporting on AI prediction models
 for macrovascular complications in T2DM patients.
- Setting: The review included studies conducted in various healthcare settings, primarily from
 LMICs, upper-middle-income countries (UMICs), and high-income countries (HICs).
- 18 **Participants: 4**6 studies were included, with a total of 184 AI models. Participants were

diverse in age, sex, and geographical locations, reflecting a broad range of healthcaresettings.

- Interventions: The intervention analyzed was the application of AI models, including machine learning algorithms, to predict macrovascular complications such as stroke, CVD, and PVD.
- Primary and Secondary Outcome Measures: The primary outcome was the predictive performance of AI models, measured by the area under the receiver operating characteristic curve (AUROC). Secondary outcomes included subgroup analyses based on predictor types and an assessment of AI model applicability in low-resource settings.
- 28 **Results:** Twelve included studies yielded 184 AI models with an overall AUROC of 0.753
- 29 (95%CI: 0.74-0.766; I2=99.99%; p<0.001). For 80 models of cardiovascular outcomes, an
- 30 AUROC of 0.741 (95%CI: 0.721-0.76; I2=99.78%; p<0.001) was obtained. Meanwhile, 25
- 31 models of peripheral vascular disease and 38 models of cerebrovascular diseases obtained
- 32 AUROCs of 0.794 (95%CI: 0.758-0.831; I2=97.23%; p<0.001) and 0.77 (95%CI: 0.743-
- 33 0.797; I2=99.73%; p<0.001) respectively. Subgroup analysis revealed that models with lab-
- 34 only predictors were superior to those with mixed or no-lab predictors. This signalled the lack

- 35 of AI capability for history-taking and physical examination data alone, primarily available in
- 36 low-resource settings.
- 37 **Conclusions:** Artificial intelligence is promising in predicting diabetes complications.
- 38 Nevertheless, future studies should explore accessible features in low-resource settings and
- 39 employ external validation to ensure the robustness of the prediction models.

40 Keywords: artificial intelligence; Diabetes Mellitus, Type 2; Stroke; Cardiovascular

- 41 Disease; Diabetic nephropathy & vascular disease;
- 42 Word Count: 3685 words

43 Article Summary

44 Strengths and limitations of this study:

45 Inclusion of studies from both health-related and computer science databases (such as ٠ 46 IEEE Xplore) ensured a comprehensive assessment of AI models for predicting diabetes complications. 47 48 The study analyzed a wide range of models from various countries with different • 49 income levels, enhancing the generalizability of the findings. 50 Detailed subgroup analyses provided insights into the impact of predictor types (lab ٠ 51 vs. non-lab) and machine learning algorithms on model performance. 52 High heterogeneity across studies, stemming from variations in populations, data ٠ 53 sources, and algorithms, was observed, reflecting a common issue in AI model 54 performance meta-analyses. A significant limitation was the lack of external validation in most included studies, 55 • 56 which raises concerns about the generalizability and applicability of the AI models in 57 diverse clinical settings. **Key Messages** 58

59 What is already known on this topic 60 Artificial intelligence (AI) holds great potential for diabetes care. 61 Previous meta-analyses have shown its promise in diabetes predictions, but 0 62 none has been done for diabetes complication predictions. 63 What this study adds AI model performance aggregates provided promising results. 64 0 65 Subgroup analyses exposed characteristics facilitating prediction 66 performances, namely gradient-boosting algorithms, lab predictors, crossvalidation, and detailed missing data. 67 How this study might affect research, practice, or policy 68 ۲ 69 Albeit promising, ethical open-source models enabling multiple external validations and interdisciplinary collaboration are vital before broader 70 71 implementation.

72 Introduction

At least 500 million people were estimated to live with diabetes in 2021, of which 96% were 73 type 2 diabetes mellitus (T2DM).¹ Diabetes complications, such as stroke, cardiovascular 74 diseases (CVD), and peripheral vascular diseases (PVD), increase the 5-year mortality, 75 particularly for people living in low- and middle-income countries (LMICs).² According to 76 World Health Organization (WHO) estimates, 75% of CVD deaths occur in LMICs.³ As the 77 global burden continues to rise, there is an urgent need for precise and early risk stratification 78 79 methods to enable timely preventive measures for T2DM complications.⁴ In this context, the use of artificial intelligence (AI) and machine learning (ML) models has garnered significant 80 interest for their potential to enhance predictive accuracy in the management of T2DM 81 complications.⁵⁶ These technologies promise to transform traditional healthcare approaches 82 83 by leveraging vast amounts of data to uncover complex patterns and relationships that may 84 not be readily apparent through conventional statistical methods.

85 Previous systematic reviews have primarily focused on the potential of AI in various aspects

86 of diabetes care, particularly in predicting the onset of diabetes itself. For instance, recent

87 meta-analyses have demonstrated the utility of AI in forecasting diabetes-related outcomes,

 $\frac{88}{10}$ yet none have comprehensively addressed the prediction of macrovascular complications

associated explicitly with T2DM.⁸⁻¹⁰ This gap highlights the necessity of a focused

90 investigation into how AI can be harnessed to predict complications like stroke, CVD, and

91 PVD in patients already diagnosed with T2DM, including its deployment in low-resource

92 settings.¹¹

93 This systematic review and meta-analysis aim to expdiabalore the performance of machine

94 learning algorithms in predicting the risk of macrovascular complications among individuals

95 with T2DM, specifically, the predictive capabilities of AI models in forecasting stroke, CVD,

96 and PVD. Unlike earlier studies that may have concentrated on a single type of complication

97 or generalized diabetes prediction, this review delves into a broader spectrum. Moreover, it

98 provides an in-depth analysis of subgroup performances, comparing models with various

99 predictor types, including lab-only and mixed predictors, and examining the implications of

these differences. This review also highlights the challenges and limitations associated with

101 current AI models, particularly their applicability in low-resource settings. By focusing on

102 models that utilize widely available data and require minimal specialized input, the findings

103 might guide future research or policy-making for AI tools that can be deployed effectively in

104 regions with limited healthcare infrastructure.

105 Materials and Methods

106 Search Strategy

107 This review was systematically developed, conducted, and reported following Preferred

108 Reporting Items for Systematic Review and Meta-Analysis (PRISMA) checklist during

109 writing our report as presented in the Supplementary Material 1.¹² Our protocol has been

110 registered at The International Prospective Register of Systematic Reviews (PROSPERO)

111 under the reference ID CRD42023489167.

112 We searched six databases (Scopus, PubMed, Embase, Wiley Online Library, IEEE Explore,

and Google Scholar) and hand-searched for articles published between January 1, 2000, and

114 November 30, 2023. Keywords employed were "type 2 diabetes", "artificial intelligence,"

115 "prediction," "complication," "stroke," "cardiovascular disease," and "peripheral vascular

116 disease," as well as their MeSH terms and subsets combined with Boolean operators (see

117 Supplementary Material 2). Search results were exported and deduplicated to Rayyan

118 (www.rayyan.ai).

119 Eligibility Criteria

120 Each article was screened for the following PICOT inclusion criteria (see Supplementary

121 Material 3) by at least two members independently (AN, ST, RH, SW):¹³ (1) subjects are

adults aged 18 years old or above with type 2 diabetes mellitus, (2) intervention was the

123 development and implementation of artificial intelligence, including but not limited to

machine learning and deep learning, as opposed to classical statistical models, (3) outcome

125 included prediction performances for stroke, cardiovascular disease, or peripheral vascular

126 disease, (4) diagnostic or prognostic studies with a cohort or case-control design capable of 127 exhibiting temporality, (5) used any actual medical dataset, and (6) published in English. We

excluded studies that (1) had mixed populations with type 1 and/or prediabetes patients, (2)

mainly explained theoretical models not tested on human subjects, (3) involved drugs as the

130 intervention, (4) were reviews, framework developments, conference abstracts, proposals,

editorials, commentaries, and qualitative studies, and (5) had irretrievable full-text. After

titles and abstracts were screened on Rayyan, full-text screening was conducted to reconfirm

133 eligibility. Discrepancies were resolved through consensus.

134 Data Extraction

135 A data extraction instrument was developed to tribulate several characteristics and details

136 from all included studies, namely (1) author and year, (2) country of origin, (3) study design,

137 (4) data source, (5) single or multi-centred, (6) population profile (including number of

138 patients, age, and proportion of males), (7) predictors, (8) whether external validation was

employed, (9) AI/ML algorithm, (10) outcome (stroke, cardiovascular disease, or peripheral

140 vascular disease), (11) data period and follow-up, (12) data pre-processing details, and (13)

141 internal validation setup. We also extracted the main outcome, model performance, in metrics

such as F-measures, the area under the receiving operating curve (AUROC), c-statistics,

sensitivity/recall, specificity, accuracy, and precision/positive predictive value.

144 **Risk of Bias Assessment**

145 Two members (AN, ST, DY, AK) independently assessed all included studies for risk of bias

and applicability using the signalling questions on the Prediction Model Risk of Bias

Assessment Tool (PROBAST).¹⁴ Differences were discussed to reach a consensus.

148 **Quantitative Data Analysis**

149 Studies reporting AUROCs as model performances were aggregated through a random-

150 effects meta-analysis with MedCalc, visualized with R. When neither the standard error,

151 range, nor the standard deviation was disclosed, we ran the Hanley and McNeil's approach¹⁵

152 with R to approximate the standard error based on the AUROC, sample size, and number of 1517

153 complication cases.¹⁵⁻¹⁷ To assess publication bias, funnel plots and Egger's regression were

154 generated with MedCalc. Moreover, outliers, defined as models whose 95% confidence

155 intervals did not overlap with the meta-analysis result, were excluded to generate sensitivity

analyses. As substantial heterogeneity remains, subgroup analyses were conducted for

157 outcome types, external validation, algorithms, country income levels, risk of bias, missing

158 data process details, cross-validation, and predictor data.

159 **Results and Discussion**

160 Study Characteristics

161 A total of 2,513 studies were found during the initial search across seven databases (PubMed,

162 Google Scholar, EMBASE, Scopus, IEEE Explore, and Wiley), in addition to hand

searching. After removing 512 duplicate records, 2,001 records were screened for their titles

and abstracts. Subsequently, 1,895 records were excluded, leaving 106 reports to be retrieved.

165 Studies without available full texts were excluded, resulting in 95 studies being assessed for

eligibility. Of these, 49 studies were excluded for various reasons: unsuitable population (17

167 studies), irrelevant outcome (29 studies), unsuitable study design (2 studies), and text not in

168 English (1 study). Ultimately, 46 studies were included in the systematic review, with 30

169 included in the quantitative analysis. The selection process is depicted in Figure 1.

170 Supplementary Material 4 depicts the overall characteristics of the study, including the

171 participants and outcomes of each study. The systematic review encompasses 46 studies from

172 various countries, which are categorized into three regions based on income levels: low-

173 middle-income countries (LMIC), upper-middle-income countries (UMIC), and high-income

174 countries (HIC). Most data were sourced from hospital medical records in the respective

175 countries, while some datasets were from specific trials or studies. Sample sizes from each

176 study varied from around a hundred to hundreds of thousands, even surpassing a million. The

177 predictors were divided into demographic, clinical, comorbidity, and laboratory groups. The

algorithms were classified into several main categories, such as Random Forest, Neural


179 Network, Gradient Boosting, Logistic Regression, Multi-task Learning, Cox-based methods,

180 and others. The outcomes assessed included cardiovascular disease, cerebrovascular disease

181 (stroke), and peripheral vascular disease. Information about technical aspects such as

182 handling missing data, cross-validation, and external validation is also provided.

183




184




Figure 1: PRISMA flowchart of included studies.

186 Risk of Bias

187 The overall risk of bias, as summarised in Figure 2, indicates that 78% of the articles are 188 rated as having a high or uncertain risk of bias, with specific distributions of 10 articles rated 189 as low risk, ten as unclear risk, and 27 as high risk. The high risk of bias predominantly 190 originated from the "outcome" domain due to the uncertainty in determining outcomes 191 without knowledge of predictor information. Additionally, the "analysis" domain contributed 192 significantly to the high risk, primarily due to inadequate handling of missing data or 193 improper imputation methods and the low number of participants with the outcome. Nearly 194 all studies (91%) showed no concerns regarding applicability concerns.



PROBAST - Applicabilty



196

197

Figure 2: PROBAST summary of included studies

198 **Meta-Analysis of AUROCs**

199 All 184 models were pooled with a random effects model, obtaining an AUROC of 0.753

200 (95%CI: 0.74–0.766; I²=99.99%; p<0.001), as shown through the forest plot in Figure 3. For

201 80 models of cardiovascular outcomes, an AUROC of 0.741 (95%CI: 0.721-0.76;

202 I^2 =99.78%; p<0.001) was obtained. Meanwhile, 25 models of peripheral vascular disease and

203 38 models of cerebrovascular diseases obtained AUROCs of 0.794 (95%CI: 0.758-0.831;

204 I^2 =97.23%; p<0.001) and 0.77 (95%CI: 0.743-0.797; I^2 =99.73%; p<0.001) respectively

205 (Supplementary Materials 6–9). Subgroup analysis results are detailed in Table 1.






Figure 3: Forest plot of artificial intelligence areas under the operating curve (AUROCs) in predicting diabetes complications.

Table 1: Subgroup analyses summary of Area Under the Receiver Operating Characteristics (AUROCs) of machine learning prediction models for diabetes macrovascular complications based on various characteristics.

Subgroups	No. of prediction models	Random- effects AUROC	Lower 95% CI	Higher 95% CI	Heterogene ity (%)	p-value
All studies	184	0.753	0.74	0.766	99.99	< 0.001
Outcome types						
Cardiovascular	80	0.741	0.721	0.76	99.78	< 0.001
Peripheral vascular/diabetic foot	25	0.794	0.758	0.831	97.23	< 0.001
Stroke / cerebrovascular	38	0.77	0.743	0.797	99.73	< 0.001
Mixed	41	0.741	0.716	0.765	100	< 0.001
External validatio		··· · •				
Yes	56	0.725	0.708	0.742	97.85	< 0.001
No	128	0.765	0.749	0.782	99.99	< 0.001
Machine learning			-			
Cox-based	14	0.712	0.664	0.76	98.53	< 0.001
Gradient boosting	37	0.789	0.761	0.817	99.56	< 0.001
Logistic regression	23	0.731	0.711	0.752	99.55	< 0.001
Multi-task learning	18	0.699	0.665	0.733	99.99	< 0.001
Neural network	10	0.759	0.722	0.797	98.55	< 0.001
Random forest	30	0.776	0.742	0.810	99.73	< 0.001
Others	51	0.752	0.726	0.777	99.99	< 0.001
Country income						
HIC	134	0.737	0.723	0.751	99.99	< 0.001
LIC/LMIC/UMI C	50	0.8	0.774	0.825	97.31	< 0.001
C Risk of bias	50	0.0	0.774	0.025	71.31	< 0.001
Low/medium	110	0.780	0.765	0.794	99.76	< 0.001
High	74	0.780	0.691	0.731	99.70 99.99	< 0.001
Missing data proc		0.711	0.071	0.7.01		. 0.001
Yes	114	0.775	0.76	0.79	99.66	< 0.001
No	70	0.717	0.696	0.738	99.99	< 0.001
Cross-validation			0.070			

127	0.759	0.743	0.775	99.99	< 0.001
57	0.739	0.717	0.761	98.88	< 0.001
29	0.714	0.696	0.731	100	< 0.001
3	0.837	0.784	0.89	0	< 0.001
152	0.759	0.745	0.774	99.98	< 0.001
	57 29 3	57 0.739 29 0.714 3 0.837	57 0.739 0.717 29 0.714 0.696 3 0.837 0.784	570.7390.7170.761290.7140.6960.73130.8370.7840.89	570.7390.7170.76198.88290.7140.6960.73110030.8370.7840.890

AUROC, Area Under the Receiver Operating Characteristic; CI, confidence interval; HIC, high-income countries; LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income countries

211 **Publication Bias**

- 212 We observed significant publication bias (Egger's test p-value = 0.0261). Funnel plots of
- 213 AUROCs against standard errors are presented in Supplementary Materials 10—14.

214 Sensitivity Analyses

215	We excluded outliers and retrieved 83 models with an overall AUROC of 0.746 (95%CI:
216	0.742-0.75; I ² =99.86%; p<0.001). This is comparable to the initial meta-analysis, showing
217	robustness despite outliers. Similarly, outcome and predictor subgroup sensitivity analyses
218	were conducted, with results in Table 2. Most notably, the peripheral vascular disease
219	outcome subgroup retrieved an AUROC of 0.820 (95%CI: 0.798–0.842; p<0.001) with a
220	heterogeneity of $I^2=0\%$. In the lab-only predictors subgroup, no outliers were identified.

221	Table 2: Sensitivity analyses summary of Area Under the Receiver Operating Characteristics (AUROCs) of
222	machine learning prediction models for diabetes macrovascular complications based on outcomes and
223	predictors.

Subgroups	No. of prediction models	Random- effects AUROC	Lower 95% CI	Higher 95% CI	Heterogene ity (%)	p-value
All studies	83	0.746	0.742	0.75	99.86	< 0.001
Outcome types						
Cardiovascular	38	0.741	0.733	0.749	80.99	< 0.001
Peripheral vascular/diabetic foot	15	0.820	0.798	0.842	0.00	< 0.001
Stroke / cerebrovascular	18	0.756	0.747	0.764	92.42	< 0.001
Mixed	16	0.737	0.729	0.745	99.97	< 0.001
External validation	on data					
No lab	15	0.710	0.703	0.718	99.90	< 0.001

Mixed	73	0.753	0.748	0.758	92.31	< 0.001

224 Discussion

225 Model Performance

226 The pooled analysis of 184 models revealed a moderate level of performance, with an overall 227 AUROC of 0.753. The models demonstrated varying performance based on the specific 228 outcome types. The models achieved an AUROC of 0.741 for cardiovascular disease 229 outcomes, while those predicting peripheral vascular disease and cerebrovascular disease had 230 higher AUROCs of 0.794 and 0.77, respectively. Nanda R et al. (2022) generated an RF 231 model with the highest AUC across all models of 0.918 to predict the risk of T2DM people developing diabetic foot ulcers.¹⁸ These results suggest that while the models are generally 232 233 robust, their effectiveness can vary depending on the specific type of predicted macrovascular 234 complication.

Heterogeneity among the included studies was notably high, with I² values approaching

236 100% across most analyses. This substantial heterogeneity underscores the variability in

237 model performance, which could stem from differences in study populations, data sources,

238 predictor variables, and machine learning algorithms used. The high heterogeneity highlights

the importance of context-specific factors in model performance and suggests that predictive

accuracy may improve when models are tailored to specific populations and settings. The

sensitivity analysis further supports the robustness of the findings. By excluding outliers, the

overall AUROC was slightly reduced to 0.746, with heterogeneity remaining high

 $(I^2=99.86\%)$. This consistency indicates that extreme values do not unduly influence the

244 overall conclusions.

245 Using these ML models for diabetes complication risk prediction might be helpful in

246 considering several limitations in several existing conventional scoring systems. For

example, the Framingham risk score, the most established risk assessment for heart disease,

248 was developed for the general population and not specific for T2DM people.¹⁹ This risk score

is designed for the general population and not specifically for people with diabetes. Risk

scores developed for general populations may have lower discriminatory ability in

251 individuals with diabetes.²⁰ Other researchers have also developed heart disease risk

assessment focus using ML models,²¹ with linear and logistic regression, and artificial neural

253 networks (ANN) often used due to their simplicity and good predictive ability.

254 Study settings

255 Most studies (29; 63%) in our review came from research in HICs, followed by UMICs (9; 256 19.6%) and LMICs (8; 17.4%). India accounts for the majority of studies from the LMICs, 257 China dominates the UMICs, and the United States leads in the HICs. This might 258 demonstrate that a country's income level influences the number of artificial intelligence 259 research and publications. A bibliometric study by Jimma (2023) mapped the publication of 260 artificial intelligence in heaming Interestingly, the United States and China are included in 261 the top nine countries, with the United States ranking first (41.84%) and China second 262 (14.70%). Our study also identified that the most productive and prominent institutions 263 funding AI research are from the United States, including the National Institutes of Health 264 and the US National Library of Medicine. The disparity in the number of studies in non-high-

265 income countries is due to limited healthcare resources. This is significant considering that 266 80% of the global population resides in developing countries, where public health issues 267 continue to rise due to rapid globalization and urbanization. Therefore, studies in developing 268 countries are crucial, as the lack of data in these regions affects the applicability of findings 269 to their specific contexts. Our study also identified that the most productive and prominent 270 institutions funding AI research are from the United States, including the National Institutes 271 of Health and the US National Library of Medicine. The disparity in the number of studies in 272 non-high-income countries is due to limited healthcare resources. This is significant 273 considering that 80% of the global population resides in developing countries, where public 274 health issues continue to rise due to rapid globalization and urbanization. Therefore, studies 275 in developing countries are crucial, as the lack of data in these regions affects the 276 applicability of findings to their specific contexts.

277 **Predictors**

278 Our study collected 250 different predictors from the 46 studies and grouped them into four

- categories: demographic (13 predictors; 5.2%), clinical (50 predictors; 20%), comorbidity (33
- predictors; 13.2%), and laboratory (154 predictors; 61.6%). 42 (91.3%) studies included
- demographics, with the most used predictors being age, sex, and race. Demographics were
- included in 42 (91.3%) studies, with age, sex, and race being the most commonly used
- predictors. Clinical factors were included in 43 (93.5%) studies, featuring predictors like
- body mass index, blood pressure, and history of antidiabetic medication. Comorbidities were considered in only 23 (50%) studies, including hypertension, heart disease, and renal
- considered in only 23 (50%) studies, including hypertension, heart disease, and renal
 diseases. Laboratory parameters were utilized in 34 (73.9%) studies, with the most frequ
- diseases. Laboratory parameters were utilized in 34 (73.9%) studies, with the most frequent predictors being HbA1c, high-density lipids, and cholesterol levels.
- 288 Testing an existing ML model in other settings needs to account for the availability of
- 289 predictor data. In low-resource settings, a model which requires laboratory parameters might
- not be difficult to test due to limited infrastructure. We created a subgroup analysis of models
- with no laboratory data (i.e., demographic, clinical, or comorbidity), with only laboratory
- data, and mixed. The AUROCs of lab-only and non-lab models are 0.837 and 0.714
- respectively. This means non-lab models were comparable and did not perform poorly $\frac{2223}{2}$ T
- 294 compared to lab parameters.^{22 23} To improve performance, several strategies can be
- employed, such as hyperparameter tuning and exploring different algorithms that can
- 296 optimize the model.²⁴

297 Model Development

- 298 Most (n=29, 63.04%) included studies that utilized k-fold cross-validation as internal
- 299 validation, similar to previous studies in diabetes risk prediction.²⁵ With this method, the data
- 300 is divided into k folds of equal size, and the model is subsequently trained and evaluated k
- 301 times, with each evaluation utilizing a different fold as the test set. ²⁵ This method is
- 302 preferable compared to the hold-out approach as the whole dataset is utilized for
- 303 development.⁶²⁵ However, like other internal validation methods (including bootstrapping),
- 304 optimism should be adjusted for in the final model.⁶
- Only 21 (45.65%) studies reported how they handled missing data, although disregarding it may lead to imbalances, consequently introducing bias and misleading results. We found that
- 307 models where missing data handling is described perform better. Reporting is essential as
- 308 imputing different central tendencies (mean, median, or mode), as missing data could lead to

different outcomes for different data distributions.²⁶ More recently, autoencoders and other 309

imputation techniques can more accurately fill in incomplete data.^{27 28} These technologies 310

311 would be beneficial for data pre-processing prior to AI model developments.

312 **Algorithm Types**

313 Interestingly, our meta-analysis found gradient boosting to be the most common ML

314 algorithm utilized, with a leading AUROC model performance of 0.789, followed by random

315 forests (AUROC 0.776). Boosting algorithms are similar to random forests as they are

316 ensemble learning algorithms, with the advantage of avoiding overfitting.^{29 30} They also work

well with categorical and numerical predictors. The third leading algorithm for performance, 317

318 neural networks (AUROC 0.759), are comparatively less utilized by studies. As they fall in

319 the deep learning category, despite their exceptional performance and capability to capture

complex relationships, they are demanding computationally as they require large datasets.³⁰ 320

321 **External Validation**

322 The uniform decrease of model performance when validated in external datasets (AUROC of

323 (0.725) compared to internal validations (AUROC of (0.765) proved that development stages

324

tend to overestimate, consistent with previous studies, such as non-AI prognostic model studies,³¹ or AI models for other purposes.^{32 33} Moreover, only 11 (23.91%) of our included 325

studies conducted external validation, despite it being a crucial step in prediction models and 326

327 prognostic research, providing the capability for clinical impact over different settings.³⁴

328 Contrarily, for some studies, such as those with small non-representative datasets or missing

predictors, an external validation may not be worth it.³⁵ Judging the overly optimistic nature 329

330 of development models, diabetes complication prediction AI models may consider multiple

331 external validations unless they are specifically made for local clinical settings.³⁶

332 **Risk of Bias**

333 An analysis of the risk of bias in published studies reveals significant issues in their design.

334 First, many studies exhibit a high or unclear risk of bias, often due to incomplete data and

335 insufficient population samplings, such as the underrepresentation of diverse patient groups

336 and inadequate consideration of critical predictors like age and laboratory results-issues

337 with data extraction, including incomplete or inconsistent datasets, further compromise

338 model accuracy and reliability. Variable follow-up intervals also affect the generalizability of results.³⁷

339

340 Second, The heavy reliance on internal validation with limited datasets from single centres is

another concern, as studies lacking external validation show a higher risk of bias. In contrast, 341

multi-center studies or those using national databases tend to have lower risk.³⁸ The future 342

343 success of machine learning prediction models hinges on high-quality, diverse training data.

344 Proper data handling, capturing heterogeneity, and incorporating complexity are essential to

345 enhance the models' applicability and reliability.³⁹

346 Way Forward

347 The application of AI and machine learning (ML) in predicting complications is in its early

348 stages, with significant potential due to the increasing complexity and volume of data. Early

349 and accurate diagnosis of macrovascular complications could enable timely treatment, but

350 this requires rigorous validation and scrutiny for effective outcomes. Enhancing reliability

- involves increasing external validation from diverse sources and promoting open-source
- 352 development and interdisciplinary collaboration. While laboratory data enhances predictive
- accuracy, reliance on such data may limit the applicability of AI models in low-resource
- 354 settings where lab facilities are not readily available. Future research should aim to improve
- 355 the predictive power of non-lab models by incorporating advanced techniques for history-
- taking and physical examination data.

357 To ensure ethical and practical AI/ML use in healthcare, it is crucial to establish a secure

358 framework focusing on data protection, secure handling, patient consent, and algorithmic

359 transparency. Addressing biases and limitations is essential for broader implementation.

360 Collaboration with policymakers, bioethicists, academics, and the broader community will be

361 vital. Future research should prioritize validation and implementation strategies to improve

the practical utility and trustworthiness of AI/ML models in clinical settings. Moreover,

363 training healthcare professionals to interpret AI-driven predictions and incorporate them into

- patient management plans will further enhance the practical utility of these tools. Finally,
- 365 continuous monitoring and updating of AI models with new data will ensure their ongoing
- accuracy and relevance in a rapidly evolving healthcare landscape.

367

368 Strengths and Limitations

With the numerous models included in the meta-analysis, we are confident that this study reflects the capability of artificial intelligence in predicting diabetes complications to date. Information technology literature, such as IEEE Xplore, yielded studies from computer science fields that would have been absent in health-related databases. The included studies were done in multiple countries of varying income levels. Additionally, the detailed subgroup analysis provides valuable insights into the factors affecting model performance, such as the

375 type of predictors (lab vs. non-lab) and the machine learning algorithms used.

376 Nevertheless, despite all relevant subgroup analyses explored, our meta-analysis has high 377 heterogeneity, which can stem from differences in study populations, data sources, and machine learning algorithms used; such a phenomenon is commonly observed in published AI model performance meta-analyses.^{33 40} Only a tiny proportion of the included studies 378 379 380 conducted external validation, a crucial step for assessing the generalizability of prediction 381 models. This lack of external validation raises concerns about the models' applicability in 382 different clinical settings. We also only analyzed AUROCs in our meta-analyses as the most 383 utilized parameter; consequently, we excluded studies using different model performance 384 parameters. Finally, the reliance on laboratory data for superior predictive accuracy may limit 385 the practical implementation of these models in low-resource settings, where such data may 386 not be readily available. Future research should focus on enhancing the performance of non-387 lab-based models to increase their applicability across diverse healthcare environments.

388 Conclusions

389 This review demonstrates the promising potential of machine learning (ML) models in

- 390 predicting macrovascular complications among individuals with type 2 diabetes mellitus
- 391 (T2DM). We reveal a moderate overall performance with significant insights into the factors
- 392 influencing predictive accuracy. However, the high heterogeneity observed among the

included studies highlights the variability in model performance, emphasizing the need for

- 394 tailored approaches based on specific populations and settings. Future studies should focus on
- 395 developing robust non-lab-based models and conducting extensive external validations to
- improve the applicability of AI models in diverse clinical settings, especially in low-resource
- 397 environments. Ultimately, the successful integration of AI and ML models in predicting
- diabetes complications will require interdisciplinary collaboration, ethical considerations, and
- 399 ongoing validation to ensure their reliability and effectiveness in real-world clinical practice.
- 400

401 **Author Contributions**

402 Aqsha Nur: Conceptualization, review protocol, article screening, data extraction, bias

- 403 assessment, writing original draft; Sydney Tjandra: Search strategy, article screening, data
- 404 extraction, bias assessment, quantitative analysis and synthesis, writing original draft;
- 405 **Defin Yumnanisha**: data extraction, bias assessment, writing original draft; **Arnold**
- 406 Keane: data extraction, bias assessment, writing original draft, writing review and
- 407 editing; Adang Bachtiar: Conceptualization, review protocol, writing review.

408 Conflicts of Interest

- The author(s) declare(s) that there is no conflict of interest regarding the publication of thispaper.
- 411 Funding Statement
- 412 None.

413 Author Contributions

- 414 Stevano Wijoyo and Rizqi Humaira (University of Indonesia) supported the initial screening
- 415 of this review. Dante Harbuwono (University of Indonesia) provided feedback on the clinical
- 416 impact of AI for diabetes, which guided the protocol of this review.

417 Acknowledgments

- 418 Stevano Wijoyo (University of Indonesia) supported the initial screening of this review.
- 419 Dante Harbuwono (University of Indonesia) and Sri Laksmiastuti (University of Trisakti)
- 420 suggested the clinical impact of AI on diabetes, which guided the protocol of this review.

421 Data Availability Statement

- 422 Data of this study are publicly available on the Open Science Framework, a public, open
- 423 access repository, at <u>https://osf.io/7gh9m/</u>. Please contact the corresponding author for any
- 424 further inquiries.

425 References

426

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes 427 prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-428 81. doi: 10.1016/j.diabres.2018.02.023 [published Online First: 20180226] 429 2. Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus–Related All Cause and 430 Cardiovascular Mortality in a National Cohort of Adults. Journal of the American 431 Heart Association 2019;8(4):e011295. doi: doi:10.1161/JAHA.118.011295 432 3. World Health Organization. Cardiovascular Diseases (CVDs) Fact Sheet: World Health 433 Organization; [Available from: https://www.who.int/news-room/fact-434 sheets/detail/cardiovascular-diseases-(cvds) accessed 2 August 2024. 435 4. Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of 436 diabetes mellitus. Nature Reviews Endocrinology 2022;18(9):525-39. doi: 437 10.1038/s41574-022-00690-7 438 5. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial 439 intelligence. Nature 2023;616(7956):259-65. doi: 10.1038/s41586-023-05881-4 440 6. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: 441 Explanation and Elaboration. Annals of Internal Medicine 2019;170(1):W1-W33. doi: 442 10.7326/m18-1377 %m 30596876 443 7. Hunter DJ, Holmes C. Where Medical Statistics Meets Artificial Intelligence. New 444 *England Journal of Medicine* 2023;389(13):1211-19. doi: 445 doi:10.1056/NEJMra2212850 446 8. Kee OT, Harun H, Mustafa N, et al. Cardiovascular complications in a diabetes prediction 447 model using machine learning: a systematic review. Cardiovasc Diabetol 448 2023;22(1):13. doi: 10.1186/s12933-023-01741-7 [published Online First: 20230119] 449 9. Chowdhury MZI, Yeasmin F, Rabi DM, et al. Predicting the risk of stroke among patients 450 with type 2 diabetes: a systematic review and meta-analysis of C-statistics. BMJ Open 451 2019;9(8):e025579. doi: 10.1136/bmjopen-2018-025579 452 10. Usman TM, Saheed YK, Nsang A, et al. A systematic literature review of machine 453 learning based risk prediction models for diabetic retinopathy progression. Artificial 454 Intelligence in Medicine 2023;143:102617. doi: 455 https://doi.org/10.1016/j.artmed.2023.102617 456 11. Ciecierski-Holmes T, Singh R, Axt M, et al. Artificial intelligence for strengthening 457 healthcare systems in low- and middle-income countries: a systematic scoping review. 458 npj Digital Medicine 2022;5(1):162. doi: 10.1038/s41746-022-00700-y 459 12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated 460 guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 461 [published Online First: 20210329]

462 463	13. Riva JJ, Malik KM, Burnie SJ, et al. What is your research question? An introduction to the PICOT format for clinicians. <i>J Can Chiropr Assoc</i> 2012;56(3):167-71.
464	14. Moons KGM, Wolff RF, Riley RD, et al. PROBAST: A Tool to Assess Risk of Bias and
465	Applicability of Prediction Model Studies: Explanation and Elaboration. Annals of
466	Internal Medicine 2019;170(1):W1-W33. doi: 10.7326/M18-1377
467	 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating
468	characteristic (ROC) curve. <i>Radiology</i> 1982;143(1):29-36. doi:
469	10.1148/radiology.143.1.7063747
470	16. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
471	Vienna2016 [cited 2024 1 May 2024]. Available from: <u>https://www.R-project.org/</u> .
472	17. Gardner J. text: Statistical Testing for AUC Data [Internet]. [cited 2024 1 May 2024].
473	Available from: <u>https://cran.r-project.org/web/packages/auctestr/auctestr.pdf</u> .
474	 Nanda R, Nath A, Patel S, Mohapatra E. Machine learning algorithm to evaluate risk
475	factors of diabetic foot ulcers and its severity. <i>Medical & Biological Engineering &</i>
476	<i>Computing</i> 2022;60(8):2349-57. doi: 10.1007/s11517-022-02617-w
477	 Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of
478	lifetime risk for coronary heart disease. <i>Am J Cardiol</i> 2004;94(1):20-4. doi:
479	10.1016/j.amjcard.2004.03.023
480	20. Chamnan P, Simmons RK, Sharp SJ, et al. Cardiovascular risk assessment scores for
481	people with diabetes: a systematic review. <i>Diabetologia</i> 2009;52(10):2001-14. doi:
482	10.1007/s00125-009-1454-0 [published Online First: 20090724]
483	21. Wang J, Wang S, Zhu MX, et al. Risk Prediction of Major Adverse Cardiovascular
484	Events Occurrence Within 6 Months After Coronary Revascularization: Machine
485	Learning Study. <i>JMIR Med Inform</i> 2022;10(4):e33395. doi: 10.2196/33395
486	[published Online First: 20220420]
487	 Nahm FS. Receiver operating characteristic curve: overview and practical use for
488	clinicians. <i>Korean J Anesthesiol</i> 2022;75(1):25-36. doi: 10.4097/kja.21209 [published
489	Online First: 20220118]
490	23. de Hond AAH, Steyerberg EW, van Calster B. Interpreting area under the receiver
491	operating characteristic curve. <i>The Lancet Digital Health</i> 2022;4(12):e853-e55. doi:
492	10.1016/S2589-7500(22)00188-1
493	24. Nematzadeh S, Kiani F, Torkamanian-Afshar M, Aydin N. Tuning hyperparameters of
494	machine learning algorithms and deep neural networks using metaheuristics: A
495	bioinformatics study on biomedical and biological cases. <i>Comput Biol Chem</i>
496	2022;97:107619. doi: 10.1016/j.compbiolchem.2021.107619 [published Online First:
497	20211224]

498	25. Mohsen F, Al-Absi HRH, Yousri NA, et al. A scoping review of artificial intelligence-
499	based methods for diabetes risk prediction. <i>npj Digital Medicine</i> 2023;6(1):197. doi:
500	10.1038/s41746-023-00933-5
501	 Imputation Analysis of Central Tendencies for Classification. 2021 IEEE International
502	IOT, Electronics and Mechatronics Conference (IEMTRONICS); 2021 21-24 April
503	2021.
504	27. Kim JC, Chung K. Multi-Modal Stacked Denoising Autoencoder for Handling Missing
505	Data in Healthcare Big Data. <i>IEEE Access</i> 2020;8:104933-43. doi:
506	10.1109/ACCESS.2020.2997255
507 508 509	 Missing Values Imputation Using Fuzzy C Means Based On Correlation of Variable. 2020 International Conference on Computational Intelligence (ICCI); 2020 8-9 Oct. 2020.
510 511	29. Wassan S, Suhail B, Mubeen R, et al. Gradient Boosting for Health IoT Federated Learning. <i>Sustainability</i> 2022;14(24):16842.
512	 Padmanabhan S, Tran TQB, Dominiczak AF. Artificial Intelligence in Hypertension:
513	Seeing Through a Glass Darkly. <i>Circ Res</i> 2021;128(7):1100-18. doi:
514	10.1161/circresaha.121.318106 [published Online First: 20210401]
515	31. Siontis GC, Tzoulaki I, Castaldi PJ, Ioannidis JP. External validation of new risk
516	prediction models is infrequent and reveals worse prognostic discrimination. <i>J Clin</i>
517	<i>Epidemiol</i> 2015;68(1):25-34. doi: 10.1016/j.jclinepi.2014.09.007 [published Online
518	First: 20141023]
519 520 521 522	32. Smith LA, Oakden-Rayner L, Bird A, et al. Machine learning and deep learning predictive models for long-term prognosis in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Lancet Digit Health</i> 2023;5(12):e872-e81. doi: 10.1016/s2589-7500(23)00177-2
523	33. Silva K, Lee WK, Forbes A, et al. Use and performance of machine learning models for
524	type 2 diabetes prediction in community settings: A systematic review and meta-
525	analysis. <i>Int J Med Inform</i> 2020;143:104268. doi: 10.1016/j.ijmedinf.2020.104268
526	[published Online First: 20200907]
527	34. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy
528	(PROGRESS) 3: prognostic model research. <i>PLoS Med</i> 2013;10(2):e1001381. doi:
529	10.1371/journal.pmed.1001381 [published Online First: 20130205]
530	35. Martens FK, Kers JG, Janssens AC. External validation is only needed when prediction
531	models are worth it (Letter commenting on: J Clin Epidemiol. 2015;68:25-34). J Clin
532	Epidemiol 2016;69:249-50. doi: 10.1016/j.jclinepi.2015.01.022 [published Online
533	First: 20150203]
534	36. Wessler BS, Nelson J, Park JG, et al. External Validations of Cardiovascular Clinical
535	Prediction Models: A Large-Scale Review of the Literature. <i>Circ Cardiovasc Qual</i>

- 536
 Outcomes 2021;14(8):e007858. doi: 10.1161/circoutcomes.121.007858 [published

 537
 Online First: 20210803]
- 37. Mora T, Roche D, Rodríguez-Sánchez B. Predicting the onset of diabetes-related
 complications after a diabetes diagnosis with machine learning algorithms. *Diabetes Research and Clinical Practice* 2023;204:110910. doi:
- 541 <u>https://doi.org/10.1016/j.diabres.2023.110910</u>
- 542 38. Du Y, Rafferty AR, McAuliffe FM, et al. An explainable machine learning-based clinical
 543 decision support system for prediction of gestational diabetes mellitus. *Scientific* 544 *Reports* 2022;12(1):1170. doi: 10.1038/s41598-022-05112-2
- 545 39. Leila Y, Allan T. Predicting Type 2 Diabetes Complications and Personalising Patient
 546 Using Artificial Intelligence Methodology. In: Anca Pantea S, ed. Type 2 Diabetes.
 547 Rijeka: IntechOpen 2020:Ch. 8.
- 548 40. Smith LA, Oakden-Rayner L, Bird A, et al. Machine learning and deep learning
 549 predictive models for long-term prognosis in patients with chronic obstructive
 550 pulmonary disease: a systematic review and meta-analysis. *The Lancet Digital Health*551 2023;5(12):e872-e81. doi: 10.1016/S2589-7500(23)00177-2

552

Identification of studies via databases and registers

